These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34635762)

  • 41. Dynamic changes in choroidal conditions during anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy.
    Nagai N; Suzuki M; Minami S; Kurihara T; Kamoshita M; Sonobe H; Watanabe K; Uchida A; Shinoda H; Tsubota K; Ozawa Y
    Sci Rep; 2019 Aug; 9(1):11389. PubMed ID: 31388029
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical outcomes in Caucasian patients with polypoidal choroidal vasculopathy.
    Agorogiannis EI; Pearce IA; Yadav S; Parry DG; Beare NAV
    Eye (Lond); 2018 Nov; 32(11):1731-1739. PubMed ID: 30002485
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy.
    Sakai T; Kato N; Kubota M; Tsuneoka H
    Graefes Arch Clin Exp Ophthalmol; 2017 Aug; 255(8):1565-1571. PubMed ID: 28601912
    [TBL] [Abstract][Full Text] [Related]  

  • 44. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
    Matsumiya W; Honda S; Otsuka K; Miki A; Nagai T; Imai H; Kusuhara S; Nakamura M
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):541-548. PubMed ID: 27687988
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CHOROIDAL VASCULAR HYPERPERMEABILITY AS A PREDICTOR OF TREATMENT RESPONSE FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Yanagi Y; Ting DSW; Ng WY; Lee SY; Mathur R; Chan CM; Yeo I; Wong TY; Cheung GCM
    Retina; 2018 Aug; 38(8):1509-1517. PubMed ID: 28704255
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Multicountry Comparison of Real-World Management and Outcomes of Polypoidal Choroidal Vasculopathy: Fight Retinal Blindness! Cohort.
    Chong Teo KY; Squirrell DM; Nguyen V; Banerjee G; Cohn A; Barthelmes D; Gemmy Cheung CM; Gillies M
    Ophthalmol Retina; 2019 Mar; 3(3):220-229. PubMed ID: 31014698
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: Two-Year Results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study.
    Wong TY; Ogura Y; Lee WK; Iida T; Chen SJ; Mitchell P; Gemmy Cheung CM; Zhang Z; Leal S; Ishibashi T;
    Am J Ophthalmol; 2019 Aug; 204():80-89. PubMed ID: 30849345
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy.
    Hosokawa M; Shiraga F; Yamashita A; Shiragami C; Ono A; Shirakata Y; Kimura S; Shiode Y; Kawata T; Hosogi M; Fujiwara A; Morizane Y
    Br J Ophthalmol; 2015 Aug; 99(8):1087-91. PubMed ID: 25712826
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optic disk melanocytoma associated with polypoidal choroidal vasculopathy lesions, after combination treatment of photodynamic therapy and intavitreal aflibercept (Eylea), a case report.
    Rouvas A; Gouliopoulos NS; Moschos MM; Theodossiadis P
    BMC Ophthalmol; 2018 Oct; 18(1):267. PubMed ID: 30309335
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy.
    Azuma K; Okubo A; Nomura Y; Zhou H; Terao R; Hashimoto Y; Asano KS; Azuma K; Inoue T; Obata R
    Sci Rep; 2020 May; 10(1):8337. PubMed ID: 32433551
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort.
    Liu S; Chhabra R
    Graefes Arch Clin Exp Ophthalmol; 2022 Nov; 260(11):3533-3542. PubMed ID: 35678837
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Kawashima Y; Oishi A; Tsujikawa A; Yamashiro K; Miyake M; Ueda-Arakawa N; Yoshikawa M; Takahashi A; Yoshimura N
    Graefes Arch Clin Exp Ophthalmol; 2015 Sep; 253(9):1471-7. PubMed ID: 25391986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
    Koh A; Lee WK; Chen LJ; Chen SJ; Hashad Y; Kim H; Lai TY; Pilz S; Ruamviboonsuk P; Tokaji E; Weisberger A; Lim TH
    Retina; 2012 Sep; 32(8):1453-64. PubMed ID: 22426346
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of One-Year Outcome of Intravitreal Aflibercept with or without Photodynamic Therapy for Polypoidal Choroidal Vasculopathy.
    Weng HY; Chen FT; Wang LU; Huang TL; Ho WT; Chang PY; Hsu YR; Chen YJ; Wang JK
    Medicina (Kaunas); 2024 Aug; 60(8):. PubMed ID: 39202592
    [No Abstract]   [Full Text] [Related]  

  • 55. Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy.
    Nishikawa K; Oishi A; Hata M; Miyake M; Ooto S; Yamashiro K; Miyata M; Tamura H; Ueda-Arakawa N; Takahashi A; Kawashima Y; Tsujikawa A
    Sci Rep; 2019 Mar; 9(1):3620. PubMed ID: 30842468
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
    Saito M; Iida T; Kano M
    Retina; 2012 Jul; 32(7):1272-9. PubMed ID: 22547209
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protocol for a randomised, double-masked, sham-controlled phase 4 study on the efficacy, safety and tolerability of intravitreal aflibercept monotherapy compared with aflibercept with adjunctive photodynamic therapy in polypoidal choroidal vasculopathy: the ATLANTIC study.
    Marques JP; Farinha C; Costa MÂ; Ferrão Â; Nunes S; Silva R
    BMJ Open; 2017 Aug; 7(8):e015785. PubMed ID: 28851779
    [TBL] [Abstract][Full Text] [Related]  

  • 58. INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: The Fujisan Study.
    Gomi F; Oshima Y; Mori R; Kano M; Saito M; Yamashita A; Iwata E; Maruko R;
    Retina; 2015 Aug; 35(8):1569-76. PubMed ID: 25830698
    [TBL] [Abstract][Full Text] [Related]  

  • 59. One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy.
    Weng HY; Huang TL; Chang PY; Wang JK
    BMC Pharmacol Toxicol; 2019 May; 20(1):29. PubMed ID: 31088543
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy.
    Wataru K; Sugiyama A; Yoneyama S; Matsubara M; Fukuda Y; Parikh R; Sakurada Y
    PLoS One; 2020; 15(2):e0229231. PubMed ID: 32092094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.